Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01411280 · ClinicalTrials.gov registry record · Phase 3
Ameliorating Attention Problems in Children With Sickle Cell Disease (SCD)
A Phase 3 study, sponsored by Temple University.
- Completed
- Registry status
- Phase 3
- Development phase
- 34
- Enrollment target
NCT01411280 is a Phase 3 study that has completed, run by Temple University. The registered enrollment target is 34 participants.
The verdict
NCT01411280, a Phase 3 study, has completed, sponsored by Temple University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 34 participants
- Enrollment target
Study Summary
The purpose of this study is to assess whether methylphenidate is effective in enhancing the cognitive performance of children with the HbSS or HbSC genotype of SCD who have sustained neurological complications on laboratory-based measures of sustained attention, reaction time, and executive functions, and indirectly, verbal short-term and long-term memory.
Interventions
- DRUG methylphenidate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2006-06 |
| Est. Completion | 2009-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01411280
The ClinicalTrials.gov registry entry for NCT01411280 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Temple University, which has 163 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which methylphenidate is the first listed.
NCT01411280 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01411280 about?
NCT01411280 is a clinical study titled "Ameliorating Attention Problems in Children With Sickle Cell Disease (SCD)". The purpose of this study is to assess whether methylphenidate is effective in enhancing the cognitive performance of children with the HbSS or HbSC genotype of SCD who have sustained neurological complications on laboratory-based measures of sustained attention, reaction time, and executive functio...
What is the current status of trial NCT01411280?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 34 participants. The study started on 2006-06. Estimated completion is 2009-05.
What interventions are being tested in trial NCT01411280?
The interventions under investigation include: methylphenidate (DRUG).
Who is sponsoring clinical trial NCT01411280?
This trial is sponsored by Temple University, which has 163 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.